Grant of Options and PDMR notification

RNS Number : 9409N

Oncimmune Holdings PLC

24 January 2019

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Grant of Options and PDMR notification

Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, announces that options to subscribe for an aggregate 321,100 ordinary shares of £0.01 each in the Company ("Ordinary Shares") were granted, on 23 January 2019, to Matthew Hall, Chief Financial Officer and Andrew Stewart, General Counsel & Company Secretary as follows:

Name	Position	Number of Share Options Awarded	Exercise price per Share
Matthew Hall	Chief Financial Officer	160,550	£1.09
Andrew Stewart	General Counsel & Company Secretary	160,550	£1.09

.

The Options have been granted under the Company's 2016 Share Option Plan and have an exercise price of £1.09, being the closing price of shares at 22 January 2019.  

Other than the grant of the Options, neither Mr Hall, Mr Stewart or their respective connected persons have any beneficial interest in the Ordinary Shares of the Company.

This announcement, including the notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	1)   Matthew Hall 2)   Andrew Stewart
2	Reason for the notification
a)	Position/status	1)   Chief Financial Officer 2)   General Counsel & Company Secretary
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Oncimmune Holdings plc
b)	LEI	213800HCYIWT6YPI1I02
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of £0.01 each
	Identification code	ISIN: GB00BYQ94H38
b)	Nature of the transaction	Grant of options
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			1) £1.09	160,550
			2) £1.09	160,550
d)	Aggregated information
	- Aggregated volume	321,100
	- Price	£1.09
e)	Date of the transaction	22 January 2019
f)	Place of the transaction	Outside a trading venue

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, John Goold

[phone]

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

[phone]

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey Neville

[e-mail]

[phone]

About Oncimmune

Beating cancer, one test at a time

Oncimmune is a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer. Oncimmune is changing how clinicians, researchers and patients view, diagnose and treat cancer. Our technology detects evidence of the body's natural response to cancer, enabling detection 4 years or more before standard clinical diagnosis. Our tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. We partner with leading developers and distributors to make our technology available globally.

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT^®-Lung and EarlyCDT^®-Liver. To date, over 155,000 tests have been performed for patients worldwide and EarlyCDT^®-Lung is being used in the largest-ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland. Oncimmune, headquartered in Nottingham, UK with a CLIA lab in Kansas, US and offices in London, UK and Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

For more information, visit www.oncimmune.com

 

END

 

 

DSHPGUACGUPBPGW